Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (707)	6/27/2003 1:46:47 PM
From: Icebrg	Read Replies (1) \| Respond to of 2240

Wilder, No, I don't know. As most cancer therapies fail it might make sense two try to develop both. It is an open question how much Medarex is able to influence business decision at Genmab. As Medarex only holds about a third of the equity their influence should be limited. On the other hand the board appears to be tilted towards the US and Medarex. It is up to the Danish shareholders to make sure that their interests are taken care of. (I see this from a Scandinavian point of view). I believe that the board is in need of some cleaning up by the way. Preferably by appointing a Danish chairman. Erik